Influenza Vaccines Market Synopsis

Influenza Vaccines Market Size is Valued at USD 7.91 Billion in 2023, and is Projected to Reach USD 14.51 Billion by 2032, Growing at a CAGR of 6.98% From 2024-2032.

The Influenza Vaccines Market covers the creation, manufacturing, and marketing of vaccines designed to prevent influenza, also referred to as flu. These vaccines are designed to target the temperatures of flu which are recognized to be constructing every year. Influenza vaccines as generated through egg-based system, Cell based, recombinant, and these vaccines are administered with injection or through nasal droplets. Since there has been a shift for the prevention of seasonal flu outbreaks, the market has become essential for global health, especially to high-risk individuals like the elder subjected to seriously sick, and children or people with weak immune systems.

• Seasonal flu has become common throughout the world which is also one of the major factors behind the growth of Influenza Vaccines Market. Since flu epidemics remain a threat and have significant impacts on morbidity and mortality, especially for the frail such as the elderly and chronic disease sufferers’ governments and health agencies are encouraging flu immunizations as a protective measure. This has put pressure on public health campaigns as well as governmental immunization programmes increasing the demand for influenza vaccines all round the world. Furthermore, the increasing occurrence of flu pandemics, for instance the H1N1, has made it very clear that vaccination should go on for new strains, as well as improve the technology used in developing the vaccines.
• A key factor is innovation technology in vaccines production and health departments collaborating to reach for the common goal. These are being replaced by cell based and recombinant DNA vaccines which are faster to make and can be further tuned towards individual strains of virus. These innovations increase the reach of flu vaccines and improve the nations immunization programs. The advancements in the healthcare industry along with favourable government policies and a rise in HC budget expenditure are helping the developed nations to go for flu vaccines. They added that rising healthcare awareness in emerging economies and the spread of immunization programs will drive the market even more in the future.

Influenza Vaccines Market Trend Analysis

Increasing Applications in the Automotive Industry

• One current trend observed in the Influenza Vaccines Market is the shift to the development of quadivalent vaccines to provide protection against four strains of Influenza including two Influenza A and two Influenza B. Quadrivalent vaccines are new and cover a wider area, which is becoming most preferred by doctors since they play an added role in giving better protection in seasons that several forms of the virus are circulating in the community. Such a shift is believed to persist over the years in pushing companies to take their time and come up with better and improved results when it comes to immunizing the population against existing and emerging viruses.
• A third emerging trend is the increase of utilization of sophisticated technologies such as recombinant DNA technology and cell-based platforms for manufacturing vaccines which can be plainly scaled up during pandemics. Such technologies help manufacturers react more effectively to mutations and viruses themselves. Flu seasons are getting unpredictable, actually new strains of flu can easily develop and to address this manufacturer are in the process of enhancing the capacity for production as well as ensuring availability of vaccines on the international market. This trend is particularly important when it comes to planning for the next global outbreak of infectious diseases where the speed with which vaccines are delivered is of paramount importance.

The Rising Awareness Of The Importance Of Flu Vaccinations.

• Increased understanding of the need for flu vaccinations in the growing economies is cutting its aggressive growth avenues for the Influenza Vaccines Market. Health and government agencies are increasing the reach of their immunization services to a broad and growing class of people, especially in developing countries. The potential of growth in the overall public healthcare markets in these regions will help create a large pool of consumers queuing up to get their flu vaccines, therefore presenting great opportunities for companies to exploit. Further, the target to rely on the provision of equal vaccine availability through the international health projects and collaborations also provides a good market background.
• Additional opportunities are available in what concerns individually tailored flu vaccines. As a result of improved understanding of genomics and increased amounts of available data, there is increased desire to create vaccines unique to general genetic type. Such an approach could greatly enhance the effectiveness of the immunization and in particular in people who have relatively low level immune response to standard vaccines. Purchasers of vaccines that are produced based on research and development to produce individuals vaccines against influenza maybe in a position of getting competitive advantage as other health care systems start offering treatment on individual basis.

Influenza Vaccines Market Segment Analysis:

Influenza Vaccines Market Segmented on the basis of type, application, and end-users.

By Vaccine Type, Trivalent Influenza Vaccines segment is expected to dominate the market during the forecast period

• By vaccine type the influenza vaccines market is divided into trivalent and quadrivalent vaccines. Trivalent influenza vaccines are designed to protect against three strains of the flu virus: The current flu season as two types of the A strain and one B strain of influenza. These were the type in use for many years but have been replaced by quadrivalent ones in the recent past. Quadrivalent vaccines are more effective form due to the fact that they provide an individual with protection for four strains, the two A strains, and two B strains, because normally the B strains that may circulate in any flu season may be more than one. They also said that the additional coverage goes some way in making quadrivalent vaccines more superior in halting flu infections and complications.

By Technology, Egg-based segment held the largest share in 2024

• The market of the influenza vaccines has been divided on the basis of technology such as egg-based, cell-based, and recombinant-based vaccines. Egg based vaccines are also known as Classical method of vaccine production whereby the virus is propagated in the hen’s eggs, collected then either killed or weakened to form the vaccine. This method has been highly used for many years and well accepted due to great performances but it may take long time to produce. Cell culture-based vaccines, in contrast, employ mammalian cell lines to culture the virus which is faster and easier as well as they lend themselves to targeted development of new strain responses. Recombinant based vaccines are a newer generation of vaccines that is attained by getting a gene of a virus into a cell and then producing a protein that is capable of triggering an immune response without use of the actual virus. This method provides better safety and more versatility that allows changing the circulating flu strains quickly. All of the technologies can be useful to offer more choices of the influenza vaccine to reach consumers in the market.

Influenza Vaccines Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America leads the Influenza Vaccines Market because of the widespread presence of state-of-art healthcare facilities, high-prescription rates of vaccination, and massive governmental support for flu vaccinations. The U.S. Centers for Disease Control and Prevention (CDC) maintains a large part of the promotion of mass influenza vaccination campaigns especially for the vulnerable population including the elderly and those patients with chronic illnesses. This has positively impacted on flu growth market in the United States through placing the right networks of healthcare providers and pharmacies to ensure delivery and administration of flu vaccines.
• In the same way, the constant involvement of some market players and improvement in technology in vaccines supports North America’s market dominance. The region currently hosts several of the major pharmaceutical firms that have undertaken aggressive investment in research to improve the quality of vaccines and their output. Other factors include good reimbursement policies, increased public health campaigns that have boosted the uptake of the technology in the region. Therefore, North America is expected to remain in a commanding position within the global Influenza Vaccines Market.

Active Key Players in the Influenza Vaccines Market

• Sanofi Pasteur (France)
• GlaxoSmithKline plc (UK)
• Seqirus (Australia)
• AstraZeneca (UK)
• Novartis AG (Switzerland)
• Moderna, Inc. (USA)
• Pfizer Inc. (USA)
• Johnson & Johnson (USA)
• CSL Limited (Australia)
• Bharat Biotech (India)
• Others

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Influenza Vaccines Market by Vaccine Type
 4.1 Influenza Vaccines Market Snapshot and Growth Engine
 4.2 Influenza Vaccines Market Overview
 4.3 Trivalent Influenza Vaccines
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Trivalent Influenza Vaccines: Geographic Segmentation Analysis
 4.4 Quadrivalent Influenza Vaccines
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Quadrivalent Influenza Vaccines: Geographic Segmentation Analysis

Chapter 5: Influenza Vaccines Market by Technology
 5.1 Influenza Vaccines Market Snapshot and Growth Engine
 5.2 Influenza Vaccines Market Overview
 5.3 Egg-based
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Egg-based: Geographic Segmentation Analysis
 5.4 Cell-based
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Cell-based: Geographic Segmentation Analysis
 5.5 Recombinant-based
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Recombinant-based: Geographic Segmentation Analysis

Chapter 6: Influenza Vaccines Market by Age Group
 6.1 Influenza Vaccines Market Snapshot and Growth Engine
 6.2 Influenza Vaccines Market Overview
 6.3 Pediatric
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Pediatric: Geographic Segmentation Analysis
 6.4 Adults
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Adults: Geographic Segmentation Analysis
 6.5 Elderly
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Elderly: Geographic Segmentation Analysis

Chapter 7: Influenza Vaccines Market by Administration Route
 7.1 Influenza Vaccines Market Snapshot and Growth Engine
 7.2 Influenza Vaccines Market Overview
 7.3 Injectable
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Injectable: Geographic Segmentation Analysis
 7.4 Nasal Spray
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Nasal Spray: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Influenza Vaccines Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 SANOFI PASTEUR (FRANCE)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 GLAXOSMITHKLINE PLC (UK)
 8.4 SEQIRUS (AUSTRALIA)
 8.5 ASTRAZENECA (UK)
 8.6 NOVARTIS AG (SWITZERLAND)
 8.7 MODERNA INC (USA)
 8.8 PFIZER INC (USA)
 8.9 JOHNSON & JOHNSON (USA)
 8.10 CSL LIMITED (AUSTRALIA)
 8.11 BHARAT BIOTECH (INDIA)
 8.12 OTHER

Chapter 9: Global Influenza Vaccines Market By Region
 9.1 Overview
 9.2. North America Influenza Vaccines Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Vaccine Type
  9.2.4.1 Trivalent Influenza Vaccines
  9.2.4.2 Quadrivalent Influenza Vaccines
  9.2.5 Historic and Forecasted Market Size By Technology
  9.2.5.1 Egg-based
  9.2.5.2 Cell-based
  9.2.5.3 Recombinant-based
  9.2.6 Historic and Forecasted Market Size By Age Group
  9.2.6.1 Pediatric
  9.2.6.2 Adults
  9.2.6.3 Elderly
  9.2.7 Historic and Forecasted Market Size By Administration Route
  9.2.7.1 Injectable
  9.2.7.2 Nasal Spray
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Influenza Vaccines Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Vaccine Type
  9.3.4.1 Trivalent Influenza Vaccines
  9.3.4.2 Quadrivalent Influenza Vaccines
  9.3.5 Historic and Forecasted Market Size By Technology
  9.3.5.1 Egg-based
  9.3.5.2 Cell-based
  9.3.5.3 Recombinant-based
  9.3.6 Historic and Forecasted Market Size By Age Group
  9.3.6.1 Pediatric
  9.3.6.2 Adults
  9.3.6.3 Elderly
  9.3.7 Historic and Forecasted Market Size By Administration Route
  9.3.7.1 Injectable
  9.3.7.2 Nasal Spray
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Influenza Vaccines Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Vaccine Type
  9.4.4.1 Trivalent Influenza Vaccines
  9.4.4.2 Quadrivalent Influenza Vaccines
  9.4.5 Historic and Forecasted Market Size By Technology
  9.4.5.1 Egg-based
  9.4.5.2 Cell-based
  9.4.5.3 Recombinant-based
  9.4.6 Historic and Forecasted Market Size By Age Group
  9.4.6.1 Pediatric
  9.4.6.2 Adults
  9.4.6.3 Elderly
  9.4.7 Historic and Forecasted Market Size By Administration Route
  9.4.7.1 Injectable
  9.4.7.2 Nasal Spray
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Influenza Vaccines Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Vaccine Type
  9.5.4.1 Trivalent Influenza Vaccines
  9.5.4.2 Quadrivalent Influenza Vaccines
  9.5.5 Historic and Forecasted Market Size By Technology
  9.5.5.1 Egg-based
  9.5.5.2 Cell-based
  9.5.5.3 Recombinant-based
  9.5.6 Historic and Forecasted Market Size By Age Group
  9.5.6.1 Pediatric
  9.5.6.2 Adults
  9.5.6.3 Elderly
  9.5.7 Historic and Forecasted Market Size By Administration Route
  9.5.7.1 Injectable
  9.5.7.2 Nasal Spray
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Influenza Vaccines Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Vaccine Type
  9.6.4.1 Trivalent Influenza Vaccines
  9.6.4.2 Quadrivalent Influenza Vaccines
  9.6.5 Historic and Forecasted Market Size By Technology
  9.6.5.1 Egg-based
  9.6.5.2 Cell-based
  9.6.5.3 Recombinant-based
  9.6.6 Historic and Forecasted Market Size By Age Group
  9.6.6.1 Pediatric
  9.6.6.2 Adults
  9.6.6.3 Elderly
  9.6.7 Historic and Forecasted Market Size By Administration Route
  9.6.7.1 Injectable
  9.6.7.2 Nasal Spray
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Influenza Vaccines Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Vaccine Type
  9.7.4.1 Trivalent Influenza Vaccines
  9.7.4.2 Quadrivalent Influenza Vaccines
  9.7.5 Historic and Forecasted Market Size By Technology
  9.7.5.1 Egg-based
  9.7.5.2 Cell-based
  9.7.5.3 Recombinant-based
  9.7.6 Historic and Forecasted Market Size By Age Group
  9.7.6.1 Pediatric
  9.7.6.2 Adults
  9.7.6.3 Elderly
  9.7.7 Historic and Forecasted Market Size By Administration Route
  9.7.7.1 Injectable
  9.7.7.2 Nasal Spray
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research